Reporting owner · CIK 0001818261

Catinazzo Thomas

SEC Form 4 history across 1 companies, 4 transactions and 3 filings.

CFOChief Financial OfficerRelay Therapeutics, Inc.
Open-market transaction mix0% buys0 buys · 4 sales

Available history · Aug 14, 2026 – Oct 06, 2026

Filings3Form 4 records
Buying$00 purchases
Selling$1M4 sales
Net value−$1MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Catinazzo Thomas transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
RLAYRelay Therapeutics, Inc.
Catinazzo ThomasCFOS · sale10b5-1 detectedSEC filing ↗-$3.96kView disclosure →
RLAYRelay Therapeutics, Inc.
Catinazzo ThomasCFOS · sale10b5-1 detectedSEC filing ↗-$325kView disclosure →
RLAYRelay Therapeutics, Inc.
Catinazzo ThomasCFOS · sale10b5-1 detectedSEC filing ↗-$335kView disclosure →
RLAYRelay Therapeutics, Inc.
Catinazzo ThomasCFOS · sale10b5-1 detectedSEC filing ↗-$349kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

sale at Relay Therapeutics, Inc. on Oct 06, 2026 valued at $3,968.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Relay Therapeutics, Inc. on Oct 06, 2026 valued at $3,968.

Review SEC filing

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Aug 202601$0.00$349,733.58-$349,733.58
Sep 202601$0.00$335,559.98-$335,559.98
Oct 202602$0.00$329,321.94-$329,321.94

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$253.7K
Median P/S size$330.5K
Direct4
Indirect0
Oct 06, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Associated companies

Companies in the disclosed reporting history

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in available history

A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

4 observations · Aug 14, 2026 – Oct 6, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 6, 2026105,134 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 14, 2026140,568Aug 18, 2026View transaction
Sep 8, 2026122,851Sep 9, 2026View transaction
Oct 6, 2026105,340Oct 8, 2026View transaction
Oct 6, 2026105,134Oct 8, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Catinazzo Thomas Insider Activity FAQ

SEC Form 4 context

Who is Catinazzo Thomas?

Catinazzo Thomas is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001818261.

Which companies has Catinazzo Thomas reported transactions for?

Relay Therapeutics, Inc.

When was Catinazzo Thomas's latest insider buy?

No open-market insider purchase is available for this period.

When was Catinazzo Thomas's latest insider sale?

sale at Relay Therapeutics, Inc. on Oct 06, 2026 valued at $3,968.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.